# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY

A. 510(k) Number: k112221   
B. Purpose for Submission: New assay   
C. Measurand: Anti-soluble liver antigen/liver pancreas (SLA/LP) antigen IgG antibodies   
D. Type of Test: Qualitative   
E. Applicant: EUROIMMUN US Inc.   
F. Proprietary and Established Names: EUROIMMUN Anti-SLA/LP (IgG)

# G. Regulatory Information:

1. Regulation section: 21 CFR $\ S 8 6 6 . 5 6 6 0$ , Multiple autoantibodies immunological test system

2. Classification: Class II

3. Product code: NIY, autoantibodies, anti-soluble liver antigen (SLA), autoimmune hepatitis

4. Panel: Immunology (82)

# H. Intended Use:

1. Intended use(s): The EUROIMMUN Anti-SLA/LP ELISA (IgG) test kit is intended for the qualitative determination of IgG class autoantibodies against SLA/LP (soluble liver antigen/liver-pancreas antigen) in human serum and plasma. It is used as an aid in the diagnosis of autoimmune hepatitis, type 1, in conjunction with other laboratory and clinical findings.

2. Indication(s) for use: Same as intended use above.

3. Special conditions for use statement(s): For prescription use only.

# 4. Special instrument requirements:

Microplate reader capable of measuring OD at $4 5 0 \mathrm { n m }$ and 620 to $6 5 0 \mathrm { n m }$ .

# I. Device Description:

The device is packaged as a kit containing: 12 microplate strips each containing 8 antigen coated wells and frame, one cut-off calibrator $( 2 0 \mathrm { R U / m L } )$ , human serumbased positive and negative controls, horseradish peroxidase (HRP)-conjugated rabbit anti-human IgG, ready-to-use sample buffer, $1 0 \mathrm { x }$ wash buffer concentrate, $^ { 3 , 3 ^ { \circ } , 5 , 5 ^ { \circ } }$ tetramethylbenzidine (TMB) substrate and sulfuric acid stop solution.

# J. Substantial Equivalence Information:

1. Predicate device name(s) and k number(s): INOVA Quanta Lite SLA ELISA, k021482

2. Comparison with predicate:

<table><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>Detection of anti-SLA/LPIgG autoantibodies to&quot;aid in the diagnosis ofautoimmune hepatitis,type 2&quot;.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Assay</td><td rowspan=1 colspan=1>ELISA</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Antigen</td><td rowspan=1 colspan=1>Recombinant SLA/LP</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Substrate</td><td rowspan=1 colspan=1>TMB</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Controls</td><td rowspan=1 colspan=1>One Positive ControlOne Negative Control</td><td rowspan=1 colspan=1>Same</td></tr></table>

<table><tr><td rowspan=1 colspan=3>Differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Assay Type</td><td rowspan=1 colspan=1>Qualitative</td><td rowspan=1 colspan=1>Semi-quantitative</td></tr><tr><td rowspan=1 colspan=1>Conjugate</td><td rowspan=1 colspan=1>Rabbit anti-human IgGlabeled with HRP</td><td rowspan=1 colspan=1>Goat anti-human IgGlabeled with HRP</td></tr><tr><td rowspan=1 colspan=1>Calibrators and Controls</td><td rowspan=1 colspan=1>1 cut-off calibrator2 controls: 1 positive, 1negative</td><td rowspan=1 colspan=1>3 controls:1 high positive, 1 lowpositive, 1 negative</td></tr><tr><td rowspan=1 colspan=1>Sample Matrix</td><td rowspan=1 colspan=1>Serum or plasma (EDTA,heparin, and citrate)</td><td rowspan=1 colspan=1>Serum only</td></tr><tr><td rowspan=1 colspan=1>Reported Units</td><td rowspan=1 colspan=1>Ratio</td><td rowspan=1 colspan=1>U/mL</td></tr><tr><td rowspan=1 colspan=1>Cut-Off Level</td><td rowspan=1 colspan=1>Ratio 1.0</td><td rowspan=1 colspan=1>25 U/mL</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

CEN 13640:2002, Stability Testing of In Vitro Diagnostic Reagents.

# L. Test Principle:

The test wells are coated with recombinant SLA/LP. The cut-off calibrator, controls, and diluted patient samples are added to the wells and autoantibodies recognizing the antigen bind during the first incubation. After washing the wells to remove all unbound proteins, conjugate is added. The conjugate binds to the captured human autoantibodies. Excess unbound conjugate is removed by another wash step. The bound conjugate is visualized with TMB substrate. Microtiter plates are read at 450 nm and a reference wavelength of 620 to $6 5 0 \mathrm { n m }$ . The controls and patient results are interpreted by comparing them as a ratio of the cut-off.

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility:

The reproducibility of the assay was assessed using patient sera with a range of values. Intra-assay reproducibility was assessed by 20 determinations on one day while inter-assay reproducibility was based on 24 determinations performed over six different days. The same samples were used in both experiments. The expected result was determined from the sample mean. The results that correctly matched the expected result were tallied. The results are summarized in the tables below:

Intra-assay reproducibility:   

<table><tr><td rowspan=1 colspan=1>Sample#</td><td rowspan=1 colspan=1>Sample MeanRatio</td><td rowspan=1 colspan=1>RatioRange</td><td rowspan=1 colspan=1>ExpectedResult</td><td rowspan=1 colspan=1># CorrectResults</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>0.2 - 0.2</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>20/20</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>0.4 - 0.4</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>20/20</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>0.8 - 0.9</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>20/20</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>1.1 - 1.2</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>20/20</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>1.1 - 1.4</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>20/20</td></tr><tr><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>1.5 - 1.7</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>20/20</td></tr><tr><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>3.6</td><td rowspan=1 colspan=1>3.4 - 3.7</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>20/20</td></tr><tr><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>4.9</td><td rowspan=1 colspan=1>4.6 - 5.3</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>20/20</td></tr></table>

Inter-assay reproducibility:   

<table><tr><td rowspan=1 colspan=1>Sample#</td><td rowspan=1 colspan=1>Sample MeanRatio</td><td rowspan=1 colspan=1>RatioRange</td><td rowspan=1 colspan=1>ExpectedResult</td><td rowspan=1 colspan=1># CorrectResults</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>0.2 - 0.3</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>24/24</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>0.3 - 0.4</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>24/24</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>0.8 - 0.9</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>24/24</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>1.0 - 1.3</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>24/24</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>1.0 - 1.3</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>24/24</td></tr><tr><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>1.6 - 1.8</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>24/24</td></tr><tr><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>3.9</td><td rowspan=1 colspan=1>3.4 - 4.2</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>24/24</td></tr><tr><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>5.4</td><td rowspan=1 colspan=1>4.7 - 5.8</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>24/24</td></tr></table>

Lot-to-lot reproducibility was assessed using patient sera with a range of values. Each sample/lot combination was tested between six and 38 times. The expected result was determined from the sample mean. The results that correctly matched the expected result were tallied. The results are summarized in the table below:

<table><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>SampleMeanRatio</td><td rowspan=1 colspan=1>RatioRange</td><td rowspan=1 colspan=1>LotsTested</td><td rowspan=1 colspan=1>Runs/Lot</td><td rowspan=1 colspan=1>TotalReplicates</td><td rowspan=1 colspan=1>ExpectedResult</td><td rowspan=1 colspan=1>#CorrectResults</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>5.6</td><td rowspan=1 colspan=1>5.4 - 6.0</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>6/6</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>7.6</td><td rowspan=1 colspan=1>7.3 - 8.0</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>6/6</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>9.7</td><td rowspan=1 colspan=1>9.5 - 9.9</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>6/6</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>0.9 - 0.9</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>6/6</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>3.1</td><td rowspan=1 colspan=1>2.1-4.1</td><td rowspan=1 colspan=1>38</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>38</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>38/38</td></tr><tr><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>3.9</td><td rowspan=1 colspan=1>3.2-4.6</td><td rowspan=1 colspan=1>38</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>38</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>38/38</td></tr><tr><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>0.1 - 0.2</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>16/16</td></tr><tr><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>0.1- 0.2</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>10/10</td></tr><tr><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>0.1 - 0.2</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>10/10</td></tr></table>

# b. Linearity/assay reportable range:

Not applicable.

c. Traceability, Stability, Expected values (controls, calibrators, or methods): There are no international standards for SLA/LP antibodies. Sample results are expressed as ratios of the cut-off calibrator.

Calibrators and Controls:

The cut-off calibrator and controls are derived from human serum and match pre-specified performance criteria. Each lot of cut-off calibrator and controls are traceable to a master lot.

# Stability studies:

Stability studies are conducted in accordance to CEN 13640:2002. Three production lots of all kit reagents were tested. Real-time stability studies ( $+ 2 ^ { \circ } \mathrm { C }$ to $+ 8 ^ { \circ } \mathrm { C }$ ) support a 12-month unopened stability claim. Other studies support that the re-constituted wash buffer is stable for up to 28 days, and the opened reagents stored at $+ 2 \mathrm { { } ^ { \circ } C }$ to $+ 8 ^ { \circ } \mathrm { C }$ are stable for 12 months.

# Sample stability:

The sponsor recommends following the guidelines in CLSI H18-A3 for sample storage.

d. Detection limit: Not applicable.

e. Analytical specificity:

Endogenous interferents: Five samples containing various levels of anti-SLA/LP levels were spiked with varying concentrations of hemoglobin up to $1 , 0 0 0 \mathrm { m g / d L }$ , triglycerides up to $2 , 0 0 0 \mathrm { m g / d L }$ , or bilirubin up to $4 0 \mathrm { m g / d L }$ . Comparison of all spiked sample/interferent combinations to the unspiked sample was within $\pm 1 5 \%$ of the original sample concentration except one; a sample with a ratio of 1.0 spiked with $4 0 \mathrm { m g / d L }$ bilirubin had $1 1 9 \%$ recovery. Lower concentrations of bilirubin in the same sample showed recovery $\pm 1 0 \%$ of the unspiked sample.

# Cross-reactivity with anti-LKM-1:

Twenty-eight (28) sera serologically positive for anti-LKM-1 antibodies were tested with the assay and found negative for anti-SLA/LP antibodies suggesting that antibodies specific for anti-LKM-1 do not bind to the SLA/LP antigen coating the assay wells. Sample ratios ranged from 0.1 to 0.7.

f. Assay cut-off: The assay cut-off is 1.0. Results $\geq 1 . 0$ are positive.

2. Comparison studies:

a. Method comparison with predicate device:

One hundred and sixty-seven (167) clinically characterized samples were tested with the predicate device and the EUROIMMUN Anti-SLA/LP ELISA (IgG). These samples were from patients with autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC), AIH/PBC overlap syndrome, and viral hepatitis. Twenty-three (23) samples intended to challenge the assay cut-off were created by mixing positive and negative samples.

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=4>Predicate</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Borderline</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>EUROIMMUNEAnti-SLA/LP ELISA</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>36</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>154</td><td rowspan=1 colspan=1>58</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>159</td><td rowspan=1 colspan=1>190</td></tr></table>

If borderline sample is considered positive:

Positive agreement $3 1 / 3 1 = 1 0 \%$ 95% CI: $8 9 . 0 \% - 1 0 0 \%$ Negative agreement $1 5 4 / 1 5 9 = 9 6 . 9 \%$ 95% CI: 92.8% - 98.6%

If borderline sample is considered negative:

Positive agreement $3 0 / 3 0 = 1 0 \%$ $9 5 \%$ CI: $8 8 . 6 \% - 1 0 0 \%$ Negative agreement $1 5 4 / 1 6 0 = 9 6 . 2 \%$ $9 5 \%$ CI: $9 2 . 1 \% - 9 8 . 3 \%$

b. Matrix comparison:

The purpose of this study was to demonstrate that the new devices give the same results for lithium heparin plasma, citrate plasma and EDTA plasma as for serum samples collected from the same patient. Normal sample pairs were spiked with anti-SLA/LP positive sera to create 16 samples that spanned the assay range. Serum sample ratios ranged from 0.3 – 8.9. As compared to serum samples, bias of the heparin plasma, citrate plasma and EDTA plasma samples ranged from $89 \%$ to $1 1 3 \%$ , $90 \%$ to $120 \%$ , and $8 8 \%$ to $1 1 5 \%$ , respectively.

3. Clinical studies:

a. Clinical Sensitivity and Specificity: Five hundred and fifteen (515) clinically characterized samples from several university, hospital, and private laboratories were analyzed with the EUROIMMUN Anti-SLA/LP ELISA (IgG) test to assess the clinical sensitivity and specificity. The patient samples consisted of 65 AIH-1, 68 AIH-2, 111 PBC, 15 AIH/PBC overlap syndrome, 47 hepatitis B, 71 hepatitis C, 19 primary sclerosing cholangitis (PSC), 24 steatohepatitis, 14 toxic liver damage, and 81 samples from other autoimmune diseases.

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=3>Autoimmune Hepatitis Type 1</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>Anti-SLA/LP</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>3*</td><td rowspan=1 colspan=1>21</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>47</td><td rowspan=1 colspan=1>447</td><td rowspan=1 colspan=1>494</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>65</td><td rowspan=1 colspan=1>450</td><td rowspan=1 colspan=1>515</td></tr></table>

\* Samples were from AIH/PBC patients

Sensitivity: $2 7 . 7 \%$ (18/65) 95% CI: $1 8 . 3 \% - 3 9 . 6 \%$ Specificity: $9 9 . 3 \%$ (447/450) 95% CI: 98.1% – 100.0% b. Other clinical supportive data: Not applicable.

The results for non-AIH-1 subjects are shown below:   

<table><tr><td rowspan=2 colspan=1>Results by Diagnosis</td><td rowspan=1 colspan=2>Anti-SLA/LP (IgG)</td></tr><tr><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Positive (%)</td></tr><tr><td rowspan=1 colspan=1>Autoimmune hepatitis type 2 (AIH-2)</td><td rowspan=1 colspan=1>68</td><td rowspan=1 colspan=1>0 (0.0%)</td></tr><tr><td rowspan=1 colspan=1>AIH/PBCoverlap syndrome</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>3 (20.0%)</td></tr><tr><td rowspan=1 colspan=1>Viral hepatitis</td><td rowspan=1 colspan=1>118</td><td rowspan=1 colspan=1>0 (0.0%)</td></tr><tr><td rowspan=1 colspan=1>Toxic liver damages</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>0 (0.0%)</td></tr><tr><td rowspan=1 colspan=1>Steatohepatitis</td><td rowspan=1 colspan=1>24</td><td rowspan=1 colspan=1>0 (0.0%)</td></tr><tr><td rowspan=1 colspan=1>Primary biliary liver cirrhosis (PBC)</td><td rowspan=1 colspan=1>111</td><td rowspan=1 colspan=1>0 (0.0%)</td></tr><tr><td rowspan=1 colspan=1>Primary sclerosing cholangitis (PSC)</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>0 (0.0%)</td></tr><tr><td rowspan=1 colspan=1>Other autoimmune diseases*</td><td rowspan=1 colspan=1>81</td><td rowspan=1 colspan=1>0 (0.0%)</td></tr></table>

\* Other autoimmune diseases include: MCTD, celiac disease, Type 1 diabetes, Hashimoto thyroiditis, Graves’ disease, and ulcerative colitis

4. Clinical cut-off: Not applicable.

5. Expected values/Reference range:

The levels of anti-SLA/LP antibodies in 150 apparently healthy blood donor samples (Caucasian, mixed age and sex) were analyzed with the EUROIMMUN Anti-SLA/LP ELISA (IgG). No samples were positive, and ratios ranged from 0 to 0.8.

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.